ENXTPA:SANPharmaceuticals
Is Sanofi (ENXTPA:SAN) Still Undervalued After Its Eczema Drug Setback?
Sanofi stock has been slightly positive over the past five years, yet its recent share price weakness and strong valuation checks suggest the market may be pricing the company more cautiously than the fundamentals imply.
Sanofi has returned about 8.4% over the past five years, which points to a modest overall gain rather than a strong long term rerating.
The expanded research collaboration with Aqemia can support long term growth expectations, while the decision to discontinue amlitelimab...